EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort Study

Merijn C.F. Mulders, Celine F. Maas, Richard A. Feelders, Wouter W. de Herder, Johannes Hofland

Journal of the National Comprehensive Cancer Network · 2026-04 · 24 (4)

DOI: 10.6004/jnccn.2025.7130 ↗
AbstractBibliografische Angaben

Abstract

Background: Carcinoid syndrome (CS), the most prevalent neuroendocrine tumor (NET)–related hormonal syndrome, is associated with impaired survival. However, the contribution of NET-specific death in patients with this syndrome is currently unknown. This study aimed to evaluate overall survival (OS), prognostic factors, and causes of death in patients with CS. Patients and Methods: We retrospectively included patients with CS treated between 1995 and 2021 at our ENETS Center of Excellence. We used Kaplan-Meier curves and log-rank tests to perform survival analyses, and a Cox proportional hazards model to calculate mortality hazard ratios (HRs). Results: A total of 295 of 427 included patients with CS died during follow-up, and cause of death was recorded in 255 patients. In 231 (90.6%) patients, the cause of death was NET-specific. Median OS was 7.1 years, and 65.1% and 34.1% of CS patients were alive at 5 and 10 years, respectively. Multivariate analysis identified age (HR, 1.06; P 940 µg/L (HR, 3.18; P 90% of mortality being NET-specific. Age, tumor grade, primary lung origin, and CgA levels were independent predictors of mortality. These findings indicate that there is an urgent need for advances in therapeutic options for patients with CS.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →